EMA Authorised: Byooviz (ranibizumab) — Samsung Bioepis NL B.V.

View source ↗

Summary

EMA authorised Byooviz (ranibizumab) from Samsung Bioepis NL B.V. for multiple retinal diseases, including wet age-related macular degeneration, macular edema, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Degenerative Myopia
• Diabetic Retinopathy
• Macular Edema
• Wet Age-related Macular Degeneration

Drugs mentioned

• BYOOVIZ (ranibizumab-nuna)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Diabetic Retinopathy;Myopia, Degenerative. MAH: Samsung Bioepis NL B.V.. Decision date: 24/02/2026